Evaluating Intravenous Carboplatin and Mirvetuximab Soravtansine for Women with Advanced Folate Receptor Alpha-Positive Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

What this Trial Is About

This research aims to evaluate the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. Mirvetuximab soravtansine is an investigational antibody drug designed to selectively target and kill cancer cells carrying FR. The study enrolls about 140 adult female participants with stage III or IV disease across approximately 80 sites in the United States. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on the first day of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. This single-group study includes regular treatment cycles over a period lasting approximately three years. During the study, participants will have frequent visits to hospitals or clinics for medical assessments, blood tests, and scans to monitor their health and response to treatment. Researchers will measure outcomes including tumor response based on independent central review, adverse events, disease control, progression-free survival, and symptom changes. Safety and treatment effects will be tracked throughout the study duration of about three years.

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.